Logo image of ABSI

ABSCI CORP (ABSI) Stock Fundamental Analysis

USA - NASDAQ:ABSI - US00091E1091 - Common Stock

4.27 USD
-0.01 (-0.12%)
Last: 10/24/2025, 8:07:40 PM
4.42 USD
+0.15 (+3.51%)
Pre-Market: 10/27/2025, 5:12:15 AM
Fundamental Rating

3

Overall ABSI gets a fundamental rating of 3 out of 10. We evaluated ABSI against 534 industry peers in the Biotechnology industry. While ABSI seems to be doing ok healthwise, there are quite some concerns on its profitability. ABSI is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

In the past year ABSI has reported negative net income.
ABSI had a negative operating cash flow in the past year.
In the past 5 years ABSI always reported negative net income.
In the past 5 years ABSI always reported negative operating cash flow.
ABSI Yearly Net Income VS EBIT VS OCF VS FCFABSI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

ABSI has a Return On Assets (-53.98%) which is in line with its industry peers.
ABSI has a Return On Equity of -65.35%. This is comparable to the rest of the industry: ABSI outperforms 59.74% of its industry peers.
Industry RankSector Rank
ROA -53.98%
ROE -65.35%
ROIC N/A
ROA(3y)-43.94%
ROA(5y)-42.38%
ROE(3y)-52.85%
ROE(5y)-52.12%
ROIC(3y)N/A
ROIC(5y)N/A
ABSI Yearly ROA, ROE, ROICABSI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200

1.3 Margins

ABSI does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ABSI Yearly Profit, Operating, Gross MarginsABSI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -500 -1K -1.5K -2K

5

2. Health

2.1 Basic Checks

ABSI does not have a ROIC to compare to the WACC, probably because it is not profitable.
ABSI has more shares outstanding than it did 1 year ago.
The number of shares outstanding for ABSI has been increased compared to 5 years ago.
The debt/assets ratio for ABSI has been reduced compared to a year ago.
ABSI Yearly Shares OutstandingABSI Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
ABSI Yearly Total Debt VS Total AssetsABSI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

An Altman-Z score of 5.51 indicates that ABSI is not in any danger for bankruptcy at the moment.
ABSI has a better Altman-Z score (5.51) than 74.53% of its industry peers.
A Debt/Equity ratio of 0.00 indicates that ABSI is not too dependend on debt financing.
ABSI has a Debt to Equity ratio (0.00) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 5.51
ROIC/WACCN/A
WACC8.64%
ABSI Yearly LT Debt VS Equity VS FCFABSI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 100M 200M 300M

2.3 Liquidity

ABSI has a Current Ratio of 4.39. This indicates that ABSI is financially healthy and has no problem in meeting its short term obligations.
ABSI has a Current ratio (4.39) which is in line with its industry peers.
ABSI has a Quick Ratio of 4.39. This indicates that ABSI is financially healthy and has no problem in meeting its short term obligations.
ABSI has a Quick ratio (4.39) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 4.39
Quick Ratio 4.39
ABSI Yearly Current Assets VS Current LiabilitesABSI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

6

3. Growth

3.1 Past

The earnings per share for ABSI have decreased by -0.64% in the last year.
The Revenue has grown by 27.48% in the past year. This is a very strong growth!
The Revenue has been growing by 17.09% on average over the past years. This is quite good.
EPS 1Y (TTM)-0.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-9.09%
Revenue 1Y (TTM)27.48%
Revenue growth 3Y-1.75%
Revenue growth 5Y17.09%
Sales Q2Q%-53.31%

3.2 Future

Based on estimates for the next years, ABSI will show a quite strong growth in Earnings Per Share. The EPS will grow by 10.52% on average per year.
Based on estimates for the next years, ABSI will show a very strong growth in Revenue. The Revenue will grow by 63.56% on average per year.
EPS Next Y5.49%
EPS Next 2Y10.01%
EPS Next 3Y10.84%
EPS Next 5Y10.52%
Revenue Next Year2.95%
Revenue Next 2Y110.74%
Revenue Next 3Y88.17%
Revenue Next 5Y63.56%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ABSI Yearly Revenue VS EstimatesABSI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M 150M
ABSI Yearly EPS VS EstimatesABSI Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -0.5 -1 -1.5 -2

0

4. Valuation

4.1 Price/Earnings Ratio

ABSI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ABSI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ABSI Price Earnings VS Forward Price EarningsABSI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ABSI Per share dataABSI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y10.01%
EPS Next 3Y10.84%

0

5. Dividend

5.1 Amount

No dividends for ABSI!.
Industry RankSector Rank
Dividend Yield N/A

ABSCI CORP

NASDAQ:ABSI (10/24/2025, 8:07:40 PM)

Premarket: 4.42 +0.15 (+3.51%)

4.27

-0.01 (-0.12%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-12 2025-08-12/amc
Earnings (Next)11-05 2025-11-05/bmo
Inst Owners60%
Inst Owner Change-0.05%
Ins Owners6.22%
Ins Owner Change0.74%
Market Cap638.45M
Revenue(TTM)4.14M
Net Income(TTM)-113296000
Analysts82.86
Price Target8.29 (94.15%)
Short Float %24.4%
Short Ratio6.08
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.25%
Min EPS beat(2)-10.99%
Max EPS beat(2)10.49%
EPS beat(4)1
Avg EPS beat(4)-4.09%
Min EPS beat(4)-13.12%
Max EPS beat(4)10.49%
EPS beat(8)1
Avg EPS beat(8)-4.03%
EPS beat(12)2
Avg EPS beat(12)-8.9%
EPS beat(16)2
Avg EPS beat(16)-13.12%
Revenue beat(2)0
Avg Revenue beat(2)-33.39%
Min Revenue beat(2)-54.7%
Max Revenue beat(2)-12.08%
Revenue beat(4)0
Avg Revenue beat(4)-33.74%
Min Revenue beat(4)-63.32%
Max Revenue beat(4)-4.87%
Revenue beat(8)0
Avg Revenue beat(8)-46.41%
Revenue beat(12)2
Avg Revenue beat(12)-35.35%
Revenue beat(16)2
Avg Revenue beat(16)-35.33%
PT rev (1m)0%
PT rev (3m)-13.8%
EPS NQ rev (1m)-3.76%
EPS NQ rev (3m)-12.39%
EPS NY rev (1m)-1.61%
EPS NY rev (3m)-4.44%
Revenue NQ rev (1m)8.27%
Revenue NQ rev (3m)-21.5%
Revenue NY rev (1m)-1.14%
Revenue NY rev (3m)-19.71%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 154.29
P/FCF N/A
P/OCF N/A
P/B 3.68
P/tB 4.9
EV/EBITDA N/A
EPS(TTM)-0.94
EYN/A
EPS(NY)-0.73
Fwd EYN/A
FCF(TTM)-0.51
FCFYN/A
OCF(TTM)-0.51
OCFYN/A
SpS0.03
BVpS1.16
TBVpS0.87
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -53.98%
ROE -65.35%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-43.94%
ROA(5y)-42.38%
ROE(3y)-52.85%
ROE(5y)-52.12%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 2.52%
Cap/Sales 7.71%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.39
Quick Ratio 4.39
Altman-Z 5.51
F-Score4
WACC8.64%
ROIC/WACCN/A
Cap/Depr(3y)44.41%
Cap/Depr(5y)179.67%
Cap/Sales(3y)101.78%
Cap/Sales(5y)229.4%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-0.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-9.09%
EPS Next Y5.49%
EPS Next 2Y10.01%
EPS Next 3Y10.84%
EPS Next 5Y10.52%
Revenue 1Y (TTM)27.48%
Revenue growth 3Y-1.75%
Revenue growth 5Y17.09%
Sales Q2Q%-53.31%
Revenue Next Year2.95%
Revenue Next 2Y110.74%
Revenue Next 3Y88.17%
Revenue Next 5Y63.56%
EBIT growth 1Y-18.48%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year10.04%
EBIT Next 3Y9.37%
EBIT Next 5YN/A
FCF growth 1Y7.48%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y0.72%
OCF growth 3YN/A
OCF growth 5YN/A

ABSCI CORP / ABSI FAQ

What is the ChartMill fundamental rating of ABSCI CORP (ABSI) stock?

ChartMill assigns a fundamental rating of 3 / 10 to ABSI.


What is the valuation status for ABSI stock?

ChartMill assigns a valuation rating of 0 / 10 to ABSCI CORP (ABSI). This can be considered as Overvalued.


How profitable is ABSCI CORP (ABSI) stock?

ABSCI CORP (ABSI) has a profitability rating of 1 / 10.


What is the expected EPS growth for ABSCI CORP (ABSI) stock?

The Earnings per Share (EPS) of ABSCI CORP (ABSI) is expected to grow by 5.49% in the next year.